Developments on antibiotics for multidrug resistant bacterial Gram-negative infections

References

• Vardakas, KZ, Rafailidis PI, Konstantelias AA, et al. Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: the study, the patient, the bug or the drug? J Infect. 2012;66(5):401–414.
   PubMed Web of Science ®Google Scholar
• Falagas, ME, Tansarli GS, Karageorgopoulos DE, et al. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis. 2014;20(7):1170–1175.
   PubMed Web of Science ®Google Scholar
• Falagas, ME, Vouloumanou EK, Samonis G, et al. Fosfomycin. Clin Microbiol Rev. 2016;29(2):321–347.
   PubMed Web of Science ®Google Scholar
• Rafailidis PI, Falagas ME. Options for treating carbapenem-resistant Enterobacteriaceae. Curr Opin Infect Dis. 2014;27(6):479–483.
   PubMed Web of Science ®Google Scholar
• Falagas, ME, Tansarli GS, Ikawa K, et al. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis. 2013;56(2):272–282.
   PubMed Web of Science ®Google Scholar
• Tacconelli, E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–327.
   PubMed Web of Science ®Google Scholar
• FDA. Establishing a list of qualifying pathogens under the food and drug administration safety and innovation act. final rule. Fed Regist. 2014;79(108):32464–32481.
   PubMedGoogle Scholar
• McEwen, A, Lawrence L, Hoover R, et al. Disposition, metabolism and mass balance of delafloxacin in healthy human volunteers following intravenous administration. Xenobiotica. 2015;45(12):1054–1062.
   PubMed Web of Science ®Google Scholar
• Timi Edeki DZ, van Den Berg F, Helen Broadhurst WC, et al. A phase I, 3-part placebo-controlled randomised trial to evaluate the safety, tolerability and pharmacokinetics of aztreonam-avibactam in healthy subjects. 2016. Available from: https://www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=48903
   Google Scholar
• Ehmann, DE, Jahić H, Ross PL, et al. Avibactam is a covalent, reversible, non-beta-lactam beta-lactamase inhibitor. Proc Natl Acad Sci U S A. 2012;109(29):11663–11668.
   PubMed Web of Science ®Google Scholar
• Lahiri, SD, Mangani S, Durand-Reville T, et al. Structural insight into potent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC beta-lactamases. Antimicrob Agents Chemother. 2013;57(6):2496–2505.
   PubMed Web of Science ®Google Scholar
• Rotschafer JC, Ostergaard BE. Combination beta-lactam and beta-lactamase-inhibitor products: antimicrobial activity and efficiency of enzyme inhibition. Am J Health Syst Pharm. 1995;52(6 Suppl 2):S15–22.
   PubMed Web of Science ®Google Scholar
• Lahiri, SD, Johnstone MR, Ross PL, et al. Avibactam and class C beta-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance. Antimicrob Agents Chemother. 2014;58(10):5704–5713.
   PubMed Web of Science ®Google Scholar
• Bonnefoy, A, Dupuis-Hamelin C, Steier V, et al. In vitro activity of AVE1330A, an innovative broad-spectrum non-beta-lactam beta-lactamase inhibitor. J Antimicrob Chemother. 2004;54(2):410–417.
   PubMed Web of Science ®Google Scholar
• Aktas Z, Kayacan C, Oncul O. In vitro activity of avibactam (NXL104) in combination with beta-lactams against Gram-negative bacteria, including OXA-48 beta-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents. 2012;39(1):86–89.
   PubMed Web of Science ®Google Scholar
• Ehmann, DE, Jahić H, Ross PL, et al. Kinetics of avibactam inhibition against Class A, C, and D beta-lactamases. J Biol Chem. 2013;288(39):27960–27971.
   PubMed Web of Science ®Google Scholar
• Abboud, MI, Damblon C, Brem J, et al. Interaction of avibactam with Class B metallo-beta-lactamases. Antimicrob Agents Chemother. 2016;60(10):5655–5662.
   PubMed Web of Science ®Google Scholar
• FDA. AVYCAZ (ceftazidime/avibactam) Full Prescribing Information. 2016. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206494s002lbl.pdf
   Google Scholar
• EMA. Summary of product characteristics ZAVICEFTA (ceftazidime/avibactam). Available from: https://www.ema.europa.eu/en/documents/product-information/zavicefta-epar-product-information_en.pdf
   Google Scholar
• Castanheira, M, Mills JC, Costello SE, et al. Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of beta-lactamase-producing strains. Antimicrob Agents Chemother. 2015;59(6):3509–3517.
   PubMed Web of Science ®Google Scholar
• Sader, HS, Castanheira M, Shortridge D, et al. Antimicrobial activity of ceftazidime-avibactam tested against multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa isolates from U.S. medical centers, 2013 to 2016. Antimicrob Agents Chemother. 2017; 61(11):e01045-17.
   Web of Science ®Google Scholar
• Karlowsky, JA, Biedenbach DJ, Kazmierczak KM, et al. Activity of ceftazidime-avibactam against extended-spectrum- and AmpC beta-lactamase-producing Enterobacteriaceae collected in the inform global surveillance study from 2012 to 2014. Antimicrob Agents Chemother. 2016;60(5):2849–2857.
   PubMed Web of Science ®Google Scholar
• Shields, RK, Clancy CJ, Hao B, et al. Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum beta-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae. Antimicrob Agents Chemother. 2015;59(9):5793–5797.
   PubMed Web of Science ®Google Scholar
• Kazmierczak, KM, de Jonge BL, Stone GG, et al. In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012–15. J Antimicrob Chemother. 2018;73(10):2777–2781.
   PubMed Web of Science ®Google Scholar
• Sader, HS, Flamm RK, Carvalhaes CG, et al. Antimicrobial susceptibility of pseudomonas aeruginosa to ceftazidime-avibactam, ceftolozane-tazobactam, piperacillin-tazobactam, and meropenem stratified by U.S. census divisions: results from the 2017 INFORM program. Antimicrob Agents Chemother. 2018;62(12):e01587-18.
   Web of Science ®Google Scholar
• ECDC. Emergence of resistance to ceftazidime-avibactam in carbapenem-resistant Enterobacteriaceae Stockholm. European Centre for Disease Prevention and Control; 2018. Available from: https://ecdc.europa.eu/sites/portal/files/documents/RRA%20-%20Emergence%20of%20resistance%20to%20CAZ-AVI%20in%20CRE%20Enterobacteriaceae%20-%20final.pdf
   Google Scholar
• Nichols, WW, Newell P, Critchley IA, et al. Avibactam pharmacokinetic/pharmacodynamic targets. Antimicrob Agents Chemother. 2018;62(6):e02446-17.
   Web of Science ®Google Scholar
• Crandon JL, Nicolau DP. Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-beta-lactamase producers. Antimicrob Agents Chemother. 2013;57(7):3299–3306.
   PubMed Web of Science ®Google Scholar
• Ramsey C, MacGowan AP. A review of the pharmacokinetics and pharmacodynamics of aztreonam. J Antimicrob Chemother. 2016;71(10):2704–2712.
   PubMed Web of Science ®Google Scholar
• Biedenbach, DJ, Kazmierczak K, Bouchillon SK, et al. In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013. Antimicrob Agents Chemother. 2015;59(7):4239–4248.
   PubMed Web of Science ®Google Scholar
• Karlowsky, JA, Kazmierczak KM, de Jonge BL, et al. In vitro activity of aztreonam-avibactam against enterobacteriaceae and Pseudomonas aeruginosa isolated by clinical laboratories in 40 countries from 2012 to 2015. Antimicrob Agents Chemother. 2017;61(9):e00472-17.
   Web of Science ®Google Scholar
• Sader, HS, Mendes RE, Pfaller MA, et al. Antimicrobial activities of aztreonam-avibactam and comparator agents against contemporary (2016) clinical enterobacteriaceae isolates. Antimicrob Agents Chemother. 2017; 62(1):e01856-17.
   PubMed Web of Science ®Google Scholar
• Castanheira M, RK Flamm HS, Jones RN, et al. Activity of aztreonam combined with the beta-lactamase inhibitor avibactam against metallo-β-lactamase-producing organisms. Escmid Abstr. 2013. Available from: https://www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=9735
   Google Scholar
• Singh, R, Kim A, Tanudra MA, et al. Pharmacokinetics/pharmacodynamics of a beta-lactam and beta-lactamase inhibitor combination: a novel approach for aztreonam/avibactam. J Antimicrob Chemother. 2015;70(9):2618–2626.
   PubMed Web of Science ®Google Scholar
• Saxon A. Aztreonam in the management of gram-negative infections in penicillin-allergic patients: a review. Pediatr Infect Dis J. 1989;8(9 Suppl): S124–7; discussion S128-32.
   PubMedGoogle Scholar
• James CW, Gurk-Turner C. Cross-reactivity of beta-lactam antibiotics. Proc (Bayl Univ Med Cent). 2001;14(1):106–107.
   PubMedGoogle Scholar
• Kishiyama JL, Adelman DC. The cross-reactivity and immunology of beta-lactam antibiotics. Drug Saf. 1994;10(4):318–327.
   PubMed Web of Science ®Google Scholar
• Lohans CT, Brem J, Schofield CJ. New Delhi Metallo-beta-lactamase 1 catalyzes avibactam and aztreonam hydrolysis. Antimicrob Agents Chemother. 2017;61(12).
   Web of Science ®Google Scholar
• FDA. VABOMRE (meropenem/vaborbactam) Full Prescribing Information. 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209776lbl.pdf
   Google Scholar
• EMA. Summary of Product Characteristics VABOMERE (meropenem/vaborbactam). Available from: https://www.ema.europa.eu/documents/product-information/vabomere-epar-product-information_en.pdf
   Google Scholar
• Zhanel, GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs. 2007;67(7):1027–1052.
   PubMed Web of Science ®Google Scholar
• Castanheira, M, Rhomberg PR, Flamm RK, et al. Effect of the beta-lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing enterobacteriaceae. Antimicrob Agents Chemother. 2016;60(9):5454–5458.
   PubMed Web of Science ®Google Scholar
• Hecker, SJ, Reddy KR, Totrov M, et al. Discovery of a cyclic boronic acid beta-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases. J Med Chem. 2015;58(9):3682–3692.
   PubMed Web of Science ®Google Scholar
• Lomovskaya, O, Sun D, Rubio-Aparicio D, et al. Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in enterobacteriaceae. Antimicrob Agents Chemother. 2017;61(11):e01443-17.
   Web of Science ®Google Scholar
• Lapuebla, A, Abdallah M, Olafisoye O, et al. Activity of a Meropenem combined with rpx7009, a novel beta-lactamase inhibitor, against gram-negative clinical isolates in New York City. Antimicrob Agents Chemother. 2015;59(8):4856–4860.
   PubMed Web of Science ®Google Scholar
• Sun, D, Rubio-Aparicio D, Nelson K, et al. Meropenem-vaborbactam resistance selection, resistance prevention, and molecular mechanisms in mutants of KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2017;61(12):e01694-17.
   Web of Science ®Google Scholar
• Castanheira, M, Huband MD, Mendes RE, et al. Meropenem-vaborbactam tested against contemporary gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017;61(9):e00567-17.
   Web of Science ®Google Scholar
• Hackel, MA, Lomovskaya O, Dudley MN, et al. In vitro activity of meropenem-vaborbactam against clinical isolates of KPC-positive Enterobacteriaceae. Antimicrob Agents Chemother. 2017;62(1):e01904-17.
   PubMed Web of Science ®Google Scholar
• Griffith, DC, Sabet M, Tarazi Z, et al. Pharmacokinetics/pharmacodynamics of vaborbactam, a novel beta-lactamase inhibitor, in combination with meropenem. Antimicrob Agents Chemother. 2018;63(1):e01659-18.
   Web of Science ®Google Scholar
• Griffith, DC, Loutit JS, Morgan EE, et al. Phase 1 study of the safety, tolerability, and pharmacokinetics of the beta-lactamase inhibitor vaborbactam (RPX7009) in healthy adult subjects. Antimicrob Agents Chemother. 2016;60(10):6326–6332.
   PubMed Web of Science ®Google Scholar
• Clissold SP, Todd PA, Campoli-Richards DM. Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1987;33(3):183–241.
   PubMed Web of Science ®Google Scholar
• Blizzard, TA, Chen H, Kim S, et al. Discovery of MK-7655, a beta-lactamase inhibitor for combination with Primaxin(R). Bioorg Med Chem Lett. 2014;24(3):780–785.
   PubMed Web of Science ®Google Scholar
• Lapuebla, A, Abdallah M, Olafisoye O, et al. Activity of imipenem with relebactam against gram-negative pathogens from New York City. Antimicrob Agents Chemother. 2015;59(8):5029–5031.
   PubMed Web of Science ®Google Scholar
• Karlowsky, JA, Lob SH, Young K, et al. Activity of imipenem/relebactam against Pseudomonas aeruginosa with antimicrobial-resistant phenotypes from seven global regions: SMART 2015–2016. J Glob Antimicrob Resist. 2018;15:140–147.
   PubMed Web of Science ®Google Scholar
• Lob, SH, Hackel MA, Kazmierczak KM, et al. In vitro activity of imipenem-relebactam against gram-negative ESKAPE pathogens isolated by clinical laboratories in the United States in 2015 (results from the SMART global surveillance program). Antimicrob Agents Chemother. 2017;61(6):e02209-16.
   PubMed Web of Science ®Google Scholar
• Livermore DM, Warner M, Mushtaq S. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother. 2013;68(10):2286–2290.
   PubMed Web of Science ®Google Scholar
• Schmidt-Malan, SM, Mishra AJ, Mushtaq A, et al. In vitro activity of imipenem-relebactam and ceftolozane-tazobactam against resistant gram-negative bacilli. Antimicrob Agents Chemother. 2018;62(8):e00533-18.
   PubMed Web of Science ®Google Scholar
• Wu, J, Racine F, Wismer MK, et al. Exploring the pharmacokinetic/pharmacodynamic relationship of relebactam (MK-7655) in combination with imipenem in a hollow-fiber infection model. Antimicrob Agents Chemother. 2018;62(5):e02323-17.
   Web of Science ®Google Scholar
• Sims, M, Mariyanovski V, McLeroth P, et al. Prospective, randomized, double-blind, phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. J Antimicrob Chemother. 2017;72(9):2616.
   PubMed Web of Science ®Google Scholar
• Lucasti, C, Vasile L, Sandesc D, et al. Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection. Antimicrob Agents Chemother. 2016;60(10):6234–6243.
   PubMed Web of Science ®Google Scholar
• Rhee, EG, Rizk ML, Calder N, et al. Pharmacokinetics, safety, and tolerability of single and multiple doses of relebactam, a beta-lactamase inhibitor, in combination with imipenem and cilastatin in healthy participants. Antimicrob Agents Chemother. 2018;62(9):e00280-18.
   Web of Science ®Google Scholar
• Juan, C, Zamorano L, Pérez JL, et al. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother. 2009;54(2):846–851.
   PubMed Web of Science ®Google Scholar
• Zhanel, GG, Chung P, Adam H, et al. Ceftolozane/tazobactam: a novel cephalosporin/beta-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs. 2013;74(1):31–51.
   Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Ge Y. Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother. 2010;65(9):1972–1974.
   PubMed Web of Science ®Google Scholar
• Sader, HS, Rhomberg PR, Farrell DJ, et al. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against enterobacteriaceae, pseudomonas aeruginosa, and bacteroides fragilis strains having various resistance phenotypes. Antimicrob Agents Chemother. 2011;55(5):2390–2394.
   PubMed Web of Science ®Google Scholar
• Bulik, CC, Tessier PR, Keel RA, et al. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms. Antimicrob Agents Chemother. 2011;56(1):544–549.
   PubMed Web of Science ®Google Scholar
• VanScoy, B, Mendes RE, Nicasio AM, et al. Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model. Antimicrob Agents Chemother. 2013;57(6):2809–2814.
   PubMed Web of Science ®Google Scholar
• EMA. Summary of product characteristics ZERBAXA (ceftolozane/tazobactam). Available from: https://www.ema.europa.eu/en/documents/product-information/zerbaxa-epar-product-information_en.pdf
   Google Scholar
• FDA. ZERBAXA (ceftolozane/tazobactam) Full Prescribing Information. U.S. Food and Drug Administration; 2014. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206829lbl.pdf
   Google Scholar
• Chandorkar, G, Huntington JA, Gotfried MH, et al. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects. J Antimicrob Chemother. 2012;67(10):2463–2469.
   PubMed Web of Science ®Google Scholar
• Xiao, AJ, Miller BW, Huntington JA, et al. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. J Clin Pharmacol. 2015;56(1):56–66.
   PubMed Web of Science ®Google Scholar
• Sader, HS, Farrell DJ, Flamm RK, et al. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). J Infect. 2016;69(3):266–277.
   Web of Science ®Google Scholar
• Sader, HS, Farrell DJ, Castanheira M, et al. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011–12). J Antimicrob Chemother. 2014;69(10):2713–2722.
   PubMed Web of Science ®Google Scholar
• Pfaller, MA, Shortridge D, Sader HS, et al. Ceftolozane/tazobactam activity against drug-resistant enterobacteriaceae and pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an antimicrobial surveillance programme (2013–2015). Int J Antimicrob Agents. 2017;51(2):181–189.
   PubMed Web of Science ®Google Scholar
• Pfaller, MA, Shortridge D, Sader HS, et al. Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013–2015). Braz J Infect Dis. 2017;21(6):627–637.
   PubMed Web of Science ®Google Scholar
• Buehrle, DJ, Shields RK, Chen L, et al. Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates. Antimicrob Agents Chemother. 2016;60(5):3227–3231.
   PubMed Web of Science ®Google Scholar
• Pfaller, MA, Bassetti M, Duncan LR, et al. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012–15). J Antimicrob Chemother. 2017;72(5):1386–1395.
   PubMed Web of Science ®Google Scholar
• Grupper M, Sutherland C, Nicolau DP. Multicenter evaluation of ceftazidime-avibactam and ceftolozane-tazobactam inhibitory activity against meropenem-nonsusceptible Pseudomonas aeruginosa from blood, respiratory tract, and wounds. Antimicrob Agents Chemother. 2017;61(10):e00875-17.
   PubMed Web of Science ®Google Scholar
• Sutcliffe, JA, O’Brien W, Fyfe C, et al. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother. 2013;57(11):5548–5558.
   PubMed Web of Science ®Google Scholar
• Zhanel, GG, Cheung D, Adam H, et al. Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs. 2016;76(5):567–588.
   PubMed Web of Science ®Google Scholar
• Grossman, TH, Starosta AL, Fyfe C, et al. Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother. 2012;56(5):2559–2564.
   PubMed Web of Science ®Google Scholar
• Zheng, JX, Lin ZW, Sun X, et al. Overexpression of OqxAB and MacAB efflux pumps contributes to eravacycline resistance and heteroresistance in clinical isolates of Klebsiella pneumoniae. Emerg Microbes Infect. 2018;7(1):139.
   PubMedGoogle Scholar
• FDA. XERAVA (eravacycline) full prescribing information. 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211109lbl.pdf
   Google Scholar
• EMA. Xerava: product information. 2018. Available from: https://www.ema.europa.eu/documents/product-information/xerava-epar-product-information_en.pdf
   Google Scholar
• Zhanel, GG, Baxter MR, Adam HJ, et al. In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014–2015. Diagn Microbiol Infect Dis. 2018;91(1):55–62.
   PubMed Web of Science ®Google Scholar
• Abdallah, M, Olafisoye O, Cortes C, et al. Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob Agents Chemother. 2014;59(3):1802–1805.
   PubMed Web of Science ®Google Scholar
• Livermore, DM, Mushtaq S, Warner M, et al. In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii. Antimicrob Agents Chemother. 2016;60(6):3840–3844.
   PubMed Web of Science ®Google Scholar
• Seifert, H, Stefanik D, Sutcliffe JA, et al. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. Int J Antimicrob Agents. 2017;51(1):62–64.
   PubMed Web of Science ®Google Scholar
• Snydman, DR, McDermott LA, Jacobus NV, et al. Evaluation of the in vitro activity of eravacycline against a broad spectrum of recent clinical anaerobic isolates. Antimicrob Agents Chemother. 2018;62(5):e02206-17.
   PubMed Web of Science ®Google Scholar
• Zhao, M, Lepak AJ, Marchillo K, et al. In vivo pharmacodynamic target assessment of eravacycline against Escherichia coli in a murine thigh infection model. Antimicrob Agents Chemother. 2017;61(7):e00250-17.
   Web of Science ®Google Scholar
• Newman, JV, Zhou J, Izmailyan S, et al. Randomized, double-blind, placebo-controlled studies of the safety and pharmacokinetics of single and multiple ascending doses of eravacycline. Antimicrob Agents Chemother. 2018;62(11):e01174-18.
   Web of Science ®Google Scholar
• Newman, JV, Zhou J, Izmailyan S, et al. Mass balance and drug interaction potential of iv eravacycline administered to healthy subjects. Antimicrob Agents Chemother; 2018:e01810-18.
   Web of Science ®Google Scholar
• Shaeer, KM, Zmarlicka MT, Chahine EB, et al. Plazomicin: a next-generation aminoglycoside. Pharmacotherapy; 2019;39(1):77–93.
   Google Scholar
• Armstrong ES, Miller GH. Combating evolution with intelligent design: the neoglycoside ACHN-490. Curr Opin Microbiol. 2010;13(5):565–573.
   PubMed Web of Science ®Google Scholar
• Aggen, JB, Armstrong ES, Goldblum AA, et al. Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob Agents Chemother. 2010;54(11):4636–4642.
   PubMed Web of Science ®Google Scholar
• Hall D, Shinabarger MT,D, Serio A, et al. Investigating the Post-Antibiotic Effect (PAE) of plazomicin against multidrug-resistant enterobacteriaceae. 2017. Available from: https://static1.squarespace.com/static/51199d96e4b084d1d0b105c3/t/59334fbc2e69cf4f364fbac9/1496534974109/ASM.Hall.Investigating+the+Post-Antibiotic+Effect+of+Plazoagainst+MDR+Enterobacteriaceae.+ASM+2017.pdf
   Google Scholar
• Zhanel, GG, Lawson CD, Zelenitsky S, et al. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Rev Anti Infect Ther. 2012;10(4):459–473.
   PubMed Web of Science ®Google Scholar
• FDA. Prescribing information for ZEMDRI. 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210303orig1s000lbl.pdf
   Google Scholar
• Walkty, A, Karlowsky JA, Baxter MR, et al. In vitro activity of plazomicin against gram-negative and gram-positive bacterial pathogens isolated from patients in canadian hospitals from 2013 to 2017 as part of the CANWARD surveillance study. Antimicrob Agents Chemother. 2018;63(1):e02068-18.
   Web of Science ®Google Scholar
• Castanheira, M, Davis AP, Mendes RE, et al. In vitro activity of plazomicin against gram-negative and gram-positive isolates collected from U.S. hospitals and comparative activities of aminoglycosides against carbapenem-resistant enterobacteriaceae and isolates carrying carbapenemase genes. Antimicrob Agents Chemother. 2018; 62(8):e00313-18.
   Web of Science ®Google Scholar
• European Medicines Agency, E.M.. Xerava: EPAR - product Ιnformation. 2018. Available from: https://www.ema.europa.eu/documents/product-information/xerava-epar-product-information_en.pdf
   Google Scholar
• Jacobs MR, Good CE, Abdelhamed AM, et al. In vitro activity of plazomicin, a next-generation aminoglycoside, against carbapenemase-producing Klebsiella pneumoniae. 2018. Available from: https://idsa.confex.com/idsa/2018/webprogram/Paper71246.html
   Google Scholar
• Connolly, LE, Riddle V, Cebrik D, et al. A multicenter, randomized, double-blind, phase 2 study of the efficacy and safety of plazomicin compared with levofloxacin in the treatment of complicated urinary tract infection and acute pyelonephritis. Antimicrob Agents Chemother. 2018;62(4):e01989-17.
   Web of Science ®Google Scholar
• Park, SM, Kim HS, Jeong YM, et al. Impact of intervention by an antimicrobial stewardship team on conversion from intravenous to oral fluoroquinolones. Infect Chemother. 2017;49(1):31–37.
   PubMed Web of Science ®Google Scholar
• Cho, JC., Crotty MP, White BP, et al. What is old is new again: delafloxacin, a modern fluoroquinolone. Pharmacotherapy. 2017;38(1):108–121.
   PubMed Web of Science ®Google Scholar
• FDA. BAXDELA full prescribing information. 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208610s000,208611s000lbl.pdf
   Google Scholar
• Kuramoto, Y, Ohshita Y, Yoshida J, et al. A novel antibacterial 8-chloroquinolone with a distorted orientation of the N1-(5-amino-2,4-difluorophenyl) group. J Med Chem. 2003;46(10):1905–1917.
   PubMed Web of Science ®Google Scholar
• So W, Crandon JL, Nicolau DP. Effects of urine matrix and ph on the potency of delafloxacin and ciprofloxacin against urogenic Escherichia coli and Klebsiella pneumoniae. J Urol. 2015;194(2):563–570.
   PubMed Web of Science ®Google Scholar
• Siala, W, Mingeot-Leclercq MP, Tulkens PM, et al. Comparison of the antibiotic activities of daptomycin, vancomycin, and the investigational fluoroquinolone delafloxacin against biofilms from Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother. 2014;58(11):6385–6397.
   PubMed Web of Science ®Google Scholar
• Lemaire S, Tulkens PM, Van Bambeke F. Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus. Antimicrob Agents Chemother. 2010;55(2):649–658.
   PubMed Web of Science ®Google Scholar
• Nilius, AM, Shen LL, Hensey-Rudloff D, et al. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob Agents Chemother. 2003;47(10):3260–3269.
   PubMed Web of Science ®Google Scholar
• Hoover, R, Hunt T, Benedict M, et al. Safety, tolerability, and pharmacokinetic properties of intravenous delafloxacin after single and multiple doses in healthy volunteers. Clin Ther. 2015;38(1):53–65.
   PubMed Web of Science ®Google Scholar
• Hoover, RK, Alcorn Jr H, Lawrence L, et al. Delafloxacin pharmacokinetics in subjects with varying degrees of renal function. J Clin Pharmacol. 2017;58(4):514–521.
   PubMed Web of Science ®Google Scholar
• Hoover, R, Marbury TC, Preston RA, et al. Clinical pharmacology of delafloxacin in patients with hepatic impairment. J Clin Pharmacol. 2016;57(3):328–335.
   PubMed Web of Science ®Google Scholar
• Almer, LS, Hoffrage JB, Keller EL, et al. In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms. Antimicrob Agents Chemother. 2004;48(7):2771–2777.
   PubMed Web of Science ®Google Scholar
• McCurdy, S, Lawrence L, Quintas M, et al. In vitro activity of delafloxacin and microbiological response against fluoroquinolone-susceptible and nonsusceptible Staphylococcus aureus isolates from two phase 3 studies of acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2017;61(9):e00772-17.
   PubMed Web of Science ®Google Scholar
• Pfaller, MA, Sader HS, Rhomberg PR, et al. In vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe, 2014. Antimicrob Agents Chemother. 2017;61(4):e02609-16.
   Web of Science ®Google Scholar
• Flamm, RK, Rhomberg PR, Huband MD, et al. In vitro activity of delafloxacin tested against isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother. 2016;60(10):6381–6385.
   PubMed Web of Science ®Google Scholar
• Pullman, J, Gardovskis J, Farley B, et al. Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a phase 3, double-blind, randomized study. J Antimicrob Chemother. 2017;72(12):3471–3480.
   PubMed Web of Science ®Google Scholar
• O‘Riordan, W, McManus A, Teras J, et al. A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized study. Clin Infect Dis. 2018;67(5):657–666.
   PubMed Web of Science ®Google Scholar
• Kingsley, J, Mehra P, Lawrence LE, et al. A randomized, double-blind, phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin. J Antimicrob Chemother. 2015;71(3):821–829.
   PubMed Web of Science ®Google Scholar
• O‘Riordan, W, Mehra P, Manos P, et al. A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections. Int J Infect Dis. 2014;30:67–73.
   PubMed Web of Science ®Google Scholar
• Lodise, T, Corey R, Hooper D, et al. Safety of delafloxacin: focus on adverse events of special interest. Open Forum Infect Dis. 2018;5(10):ofy220.
   PubMed Web of Science ®Google Scholar
• Litwin, JS, Benedict MS, Thorn MD, et al. A thorough QT study to evaluate the effects of therapeutic and supratherapeutic doses of delafloxacin on cardiac repolarization. Antimicrob Agents Chemother. 2015;59(6):3469–3473.
   PubMed Web of Science ®Google Scholar
• Kohira, N, West J, Ito A, et al. In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains. Antimicrob Agents Chemother. 2015;60(2):729–734.
   PubMed Web of Science ®Google Scholar
• Mollmann, U, Heinisch L, Bauernfeind A, et al. Siderophores as drug delivery agents: application of the “Trojan Horse” strategy. Biometals. 2009;22(4):615–624.
   PubMed Web of Science ®Google Scholar
• Ito, A, Kohira N, Bouchillon SK, et al. In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. J Antimicrob Chemother. 2015;71(3):670–677.
   PubMed Web of Science ®Google Scholar
• Monogue, ML, Tsuji M, Yamano Y, et al. Efficacy of humanized exposures of cefiderocol (S-649266) against a diverse population of Gram-negative bacteria in a murine thigh infection model. Antimicrob Agents Chemother. 2017;61(11):e01022-17.
   Web of Science ®Google Scholar
• Ghazi, IM, Monogue ML, Tsuji M, et al. Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model. Int J Antimicrob Agents. 2017;51(2):206–212.
   PubMed Web of Science ®Google Scholar
• Hackel, MA, Tsuji M, Yamano Y, et al. In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant Gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 study). Antimicrob Agents Chemother. 2017;61(9):e00093-17.
   Web of Science ®Google Scholar
• Dobias, J, Dénervaud-Tendon V, Poirel L, et al. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens. Eur J Clin Microbiol Infect Dis. 2017;36(12):2319–2327.
   PubMed Web of Science ®Google Scholar
• Matsumoto, S, Singley CM, Hoover J, et al. Efficacy of cefiderocol against carbapenem-resistant gram-negative bacilli in immunocompetent-rat respiratory tract infection models recreating human plasma pharmacokinetics. Antimicrob Agents Chemother. 2017;61(9):e00700-17.
   Web of Science ®Google Scholar
• Hsueh, SC, Lee YJ, Huang YT, et al. In vitro activities of cefiderocol, ceftolozane/ tazobactam,ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan. J Antimicrob Chemother. 2019;74(2):380–386.
   Google Scholar
• Ito-Horiyama, T, Ishii Y, Ito A, et al. Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases. Antimicrob Agents Chemother. 2016;60(7):4384–4386.
   PubMed Web of Science ®Google Scholar
• Poirel L, Kieffer N, Nordmann P. Stability of cefiderocol against clinically significant broad-spectrum oxacillinases. Int J Antimicrob Agents. 2018;52(6):866–867.
   PubMed Web of Science ®Google Scholar
• Jacobs, MR, Abdelhamed AM, Good CE, et al. ARGONAUT-I: activity of cefiderocol (S-649266), a siderophore cephalosporin, against Gram-negative bacteria, including carbapenem-resistant nonfermenters and Enterobacteriaceae with defined extended-spectrum beta-lactamases and carbapenemases. Antimicrob Agents Chemother. 2018;63(1):e01801-18.
   PubMed Web of Science ®Google Scholar
• Ghazi, IM, Monogue ML, Tsuji M, et al. Humanized exposures of cefiderocol, a siderophore cephalosporin, display sustained in vivo activity against siderophore-resistant Pseudomonas aeruginosa. Pharmacology. 2018;101(5–6):278–284.
   PubMed Web of Science ®Google Scholar
• Falagas, ME, Skalidis T, Vardakas KZ, et al. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals. J Antimicrob Chemother. 2017;72(6):1704–1708.
   PubMed Web of Science ®Google Scholar
• Kazmierczak, KM, Tsuji M, Wise MG, et al. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-beta-lactamase-producing isolates (SIDERO-WT-2014 Study). Int J Antimicrob Agents. 2018;73(10):2777–2781.
   PubMed Web of Science ®Google Scholar
• Karlowsky, JA, Hackel MA, Tsuji M, et al. In vitro activity of cefiderocol, a siderophore cephalosporin, against Gram-negative bacilli isolated by clinical laboratories in North America and Europe in 2015–2016: SIDERO-WT-2015. Int J Antimicrob Agents. 2019;53(4):456–466.
   Web of Science ®Google Scholar
• Kanazawa, S, Sato T, Kohira N, et al. Susceptibility of imipenem-susceptible but meropenem-resistant blaIMP-6-carrying enterobacteriaceae to various antibacterials, including the siderophore cephalosporin cefiderocol. Antimicrob Agents Chemother. 2017;61(7):e00576-17.
   PubMed Web of Science ®Google Scholar
• Katsube, T, Wajima T, Ishibashi T, et al. Pharmacokinetic/pharmacodynamic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, for dose adjustment based on renal function. Antimicrob Agents Chemother. 2016;61(1):e01381-16.
   PubMed Web of Science ®Google Scholar
• Kawaguchi, N, Katsube T, Echols R, et al. Population pharmacokinetic analysis of cefiderocol, a parenteral siderophore cephalosporin, in healthy subjects, subjects with various degrees of renal function, and patients with complicated urinary tract infection or acute uncomplicated pyelonephritis. Antimicrob Agents Chemother. 2018;62(2):e01391-17.
   PubMed Web of Science ®Google Scholar
• Saisho, Y, Katsube T, White S, et al. Pharmacokinetics, safety, and tolerability of cefiderocol, a novel siderophore cephalosporin for Gram-negative bacteria, in healthy subjects. Antimicrob Agents Chemother. 2018;62(3):e02163-17.
   PubMed Web of Science ®Google Scholar
• Emrich, NC, Heisig A, Stubbings W, et al. Antibacterial activity of finafloxacin under different pH conditions against isogenic strains of Escherichia coli expressing combinations of defined mechanisms of fluoroquinolone resistance. J Antimicrob Chemother. 2010;65(12):2530–2533.
   PubMed Web of Science ®Google Scholar
• Stubbings, W, Leow P, Yong GC, et al. In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions. Antimicrob Agents Chemother. 2011;55(9):4394–4397.
   PubMed Web of Science ®Google Scholar
• Higgins, PG, Stubbings W, Wisplinghoff H, et al. Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates. Antimicrob Agents Chemother. 2010;54(4):1613–1615.
   PubMed Web of Science ®Google Scholar
• Dalhoff A, Schubert S, Vente A. Pharmacodynamics of finafloxacin, ciprofloxacin, and levofloxacin in serum and urine against TEM- and SHV-type extended-spectrum-beta-lactamase-producing enterobacteriaceae isolates from patients with urinary tract infections. Antimicrob Agents Chemother. 2017;61(5):e02446-16.
   Web of Science ®Google Scholar
• Lyberatos, C, Ladas S, Ladas I, et al. Erythrocyte uroporphyrinogen-I-synthase activity in beta-thalassaemic patients. Eur J Clin Invest. 1983;13(6):461–463.
   PubMed Web of Science ®Google Scholar
• Genzel, GH, Stubbings W, Stingu CS, et al. Activity of the investigational fluoroquinolone finafloxacin and seven other antimicrobial agents against 114 obligately anaerobic bacteria. Int J Antimicrob Agents. 2014;44(5):420–423.
   PubMed Web of Science ®Google Scholar
• Idelevich, EA, Kriegeskorte A, Stubbings W, et al. Comparative in vitro activity of finafloxacin against staphylococci displaying normal and small colony variant phenotypes. J Antimicrob Chemother. 2011;66(12):2809–2813.
   PubMed Web of Science ®Google Scholar
• Patel, H, Andresen A, Vente A, et al. Human pharmacokinetics and safety profile of finafloxacin, a new fluoroquinolone antibiotic, in healthy volunteers. Antimicrob Agents Chemother. 2011;55(9):4386–4393.
   PubMed Web of Science ®Google Scholar
• Taubert, M, Chiesa J, Lückermann M, et al. Pharmacokinetics of intravenous finafloxacin in healthy volunteers. Antimicrob Agents Chemother. 2017;61(10):e01122-17.
   PubMed Web of Science ®Google Scholar
• Vente, A, Bentley C, Lückermann M, et al. Early clinical assessment of the antimicrobial activity of finafloxacin compared to ciprofloxacin in subsets of microbiologically characterized isolates. Antimicrob Agents Chemother. 2018;62(4):e02325-17.
   Web of Science ®Google Scholar
• Wagenlehner, F, Nowicki M, Bentley C, et al. Explorative randomized Phase II clinical study of the efficacy and safety of finafloxacin versus ciprofloxacin for treatment of complicated urinary tract infections. Antimicrob Agents Chemother. 2018;62(4):e02317-17.
   PubMed Web of Science ®Google Scholar
• Dillon C, Guarascio AJ, Covvey JR. Lefamulin: a promising new pleuromutilin antibiotic in the pipeline. Expert Rev Anti Infect Ther. 2019;17(1):5-15.
   Web of Science ®Google Scholar
• Veve MP, Wagner JL. Lefamulin: review of a promising novel pleuromutilin antibiotic. Pharmacotherapy. 2018;38(9):935–946.
   PubMed Web of Science ®Google Scholar
• Jacobsson, S, Paukner S, Golparian D, et al. In Vitro activity of the novel pleuromutilin lefamulin (BC-3781) and effect of efflux pump inactivation on multidrug-resistant and extensively drug-resistant Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2017;61(11):e01497-17.
   PubMed Web of Science ®Google Scholar
• Paukner S, Riedl R. Pleuromutilins: potent drugs for resistant bugs-mode of action and resistance. Cold Spring Harb Perspect Med. 2016;7(1).
   Web of Science ®Google Scholar
• Mittal, J, Szymczak WA, Guo Y, et al. Two for the price of one: emerging carbapenemases in a returning traveller to New York City. BMJ Case Rep. 2018;2018:bcr-2018-225440.
   Google Scholar
• Hobson, CA, Bonacorsi S, Fahd M, et al. Successful treatment of a bacteremia due to NDM-1-producing Morganella morganii with Aztreonam and Ceftazidime-avibactam combination in a pediatric patient with hematologic malignancy. Antimicrob Agents Chemother. 2018;63:e02463–18.
   Web of Science ®Google Scholar
• Barlow G, Morice A. Successful treatment of resistant Burkholderia multivorans infection in a patient with cystic fibrosis using ceftazidime/avibactam plus aztreonam. J Antimicrob Chemother. 2018;73(8):2270–2271.
   PubMed Web of Science ®Google Scholar